| 0.15 -0.01 (-6.25%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.27 | 1-year : | 0.35 |
| Resists | First : | 0.23 | Second : | 0.3 |
| Pivot price | 0.16  |
|||
| Supports | First : | 0.11 | Second : | 0.09 |
| MAs | MA(5) : | 0.15  |
MA(20) : | 0.15 |
| MA(100) : | 1.71 |
MA(250) : | 2.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.4 |
D(3) : | 36.7 |
| RSI | RSI(14): 32.7 |
|||
| 52-week | High : | 6.69 | Low : | 0.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRPH ] has closed above bottom band by 22.9%. Bollinger Bands are 96.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.16 - 0.16 | 0.16 - 0.17 |
| Low: | 0.14 - 0.14 | 0.14 - 0.14 |
| Close: | 0.16 - 0.16 | 0.16 - 0.16 |
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Sat, 28 Feb 2026
PRPH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Tue, 03 Feb 2026
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative - Yahoo Finance
Tue, 03 Feb 2026
Cancer test sale, COVID claim cash pursuit could transform ProPhase - Stock Titan
Mon, 22 Dec 2025
ProPhase Labs (PRPH) Stock News: Reverse Merger LOI With ABL, 1-for-10 Reverse Split Takes Effect Dec. 22, 2025 - TechStock²
Fri, 19 Dec 2025
ProPhase’s proposed ABL merger could mean cash payout for holders - Stock Titan
Fri, 19 Dec 2025
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 3.3 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -19.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | 0 % |
| Operating Margin | -539.6 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -220.4 % |
| Qtrly Rev. Growth | -37.6 % |
| Gross Profit (p.s.) | 0.2 |
| Sales Per Share | 1.06 |
| EBITDA (p.s.) | -5.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.09 |
| Price to Sales | 0.14 |
| Price to Cash Flow | -0.07 |
| Dividend | 3 |
| Forward Dividend | 0 |
| Dividend Yield | 2000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|